Concourse Financial Group Securities, Inc. Poseida Therapeutics, Inc. Transaction History

Concourse Financial Group Securities, Inc.

$1.52 Billion
Q1 2024

Number of Shares

Previous 0 NaN%

Holding current value

Previous $0 NaN%

% of portfolio

0.0%

Previous 0.0%

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 Apr 30, 2024	BUY	$2.76 - $4.13 $0 - $0	0 New	0 $0
Q4 2023 Feb 07, 2024	BUY	$1.83 - $3.51 $0 - $0	0 New	0 $0
Q3 2023 Oct 30, 2023	BUY	$1.62 - $2.79 $0 - $0	0 New	0 $0
Q3 2023 Oct 25, 2023	BUY	$1.62 - $2.79 $0 - $0	0 New	0 $0
Q2 2023 Aug 10, 2023	BUY	$1.66 - $3.4 $0 - $0	0 New	0 $0

Q1 2023 May 15, 2023	BUY	$3.08 - $8.73 $0 - $0	0 New	0 $0
Q4 2022 Jan 30, 2023	BUY	$4.04 - $6.38 $0 - $0	0 New	0 $0
Q3 2022 Nov 15, 2022	BUY	$2.43 - $4.51 $0 - $0	0 New	0 $0
Q2 2022 Aug 09, 2022	BUY	$1.87 - $5.0 $0 - $0	0 New	0 $0
Q1 2022 May 09, 2022	BUY	$3.22 - $7.04 $0 - $0	0 New	0 $0
Q4 2021 Feb 07, 2022	BUY	$6.23 - $7.6 $0 - $0	0 New	0 $0
Q3 2021 Nov 09, 2021	BUY	$7.09 - $10.71 $0 - $0	0 New	0 $0
Q2 2021 Aug 13, 2021	BUY	$7.96 - $10.07 $0 - $0	0 New	0 $0
Q1 2021 May 13, 2021	BUY	$8.51 - $11.91 $0 - $0	0 New	0 $0
Q4 2020 Feb 02, 2021	BUY	$8.29 - $11.7 $0 - $0	0 New	0 $0
Q3 2020 Nov 13, 2020	BUY	$8.09 - $16.25 $0 - $0	0 New	0 $0

Others Institutions Holding PSTX

# of Institutions

Shares Held

38.1M

Call Options Held

255K

Put Options Held

62K

Pentwater Capital Management LP Naples, FL

5.98M
Shares

$17.9 Million
0.2% of portfolio
Black Rock Inc. New York, NY

4.95M
Shares

$14.8 Million
0.0% of portfolio
Boxer Capital, LLC San Diego, CA

4.48M
Shares

$13.4 Million
0.74% of portfolio
Silverarc Capital Management, LLC

3.6M
Shares

$10.8 Million
3.85% of portfolio
Vanguard Group Inc Valley Forge, PA

3.37M
Shares

$10.1 Million
0.0% of portfolio

View Full List

About Poseida Therapeutics, Inc.

Ticker PSTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 85,775,600
Market Cap $256M
Description
Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company develops P-PSMA-101, an autologous chimeric antigen receptor T cell (CAR-T) product candidate that is in Phase I trial for the treatment of patients with metastatic castrate resistant ...

More about PSTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Concourse Financial Group Securities, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Concourse Financial Group Securities, Inc. with notifications on news.

Account